Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01747915
Other study ID # A0081105
Secondary ID 2010-023263-18
Status Completed
Phase Phase 3
First received
Last updated
Start date April 3, 2013
Est. completion date February 20, 2019

Study information

Verified date August 2019
Source Pfizer
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study is designed to evaluate the safety, tolerability and efficacy of two doses of pregabalin as add-on treatment in pediatric and adult subjects with Primary Generalized Tonic-Clonic (PGTC) seizures as compared to placebo. It is hypothesized that both doses of pregabalin will demonstrated superior efficacy when compared to placebo by reducing PGTC seizure frequency and that pregabalin will be safe and well tolerated.


Recruitment information / eligibility

Status Completed
Enrollment 219
Est. completion date February 20, 2019
Est. primary completion date February 20, 2019
Accepts healthy volunteers No
Gender All
Age group 5 Years to 65 Years
Eligibility Inclusion Criteria: - Seizures classified as Primary Generalized Tonic Clonic Seizures - Must have at least 1 PGTC seizure in the 8 weeks prior to screening - Must have a minimum of 3 PGTC seizures during the 8-week baseline phase and at least 1 PGTC in each 4-week period of the baseline phase - Currently receiving adequate and stable dosage of 1 to 3 anti-epileptic treatments (stable within 28 days of screening) - Signed informed consent and assent if a minor - Ability to comply with daily seizure and dosing diary requirements and all study procedures Exclusion Criteria: - A current diagnosis of febrile seizures, or seizures related to an ongoing acute medical illness - Focal seizures (simple partial, complex partial, or partial becoming secondarily generalized) - Status Epilepticus within 1 year prior to screening - Lennox-Gastaut syndrome, infantile spasms, Benign Epilepsy with Centrotemporal Spikes (BECTS) and Dravet syndrome - Seizures related to drugs, alcohol, or acute medical illness - Any change in anti-epileptic treatment regimen (type of medication or dose; VNS alteration) within 28 days of the screening visit or during the baseline phase - Progressive or potentially progressive structural CNS lesion or a progressive encephalopathy. - Progressive inborn errors of metabolism.

Study Design


Related Conditions & MeSH terms

  • Generalized Tonic Clonic Seizures
  • Seizures

Intervention

Drug:
Pregabalin Dose Level 1
Pregabalin, either liquid or capsule, dosed twice daily, escalated up to a maximum of 300 mg/day beginning at Randomization to Taper Phase, then tapered down to a maximum dose of 150 mg/day during 1 week Taper Phase to End of Study/Early Termination.
Pregabalin Dose Level 2
Pregabalin, either liquid or capsule, dosed twice daily, escalated up to a maximum of 600 mg/day beginning at Randomization to Taper Phase, then tapered down to a maximum of 150 mg/day during 1 week Taper Phase to End of Study/Early Termination.
Placebo
Placebo, either liquid or capsule, dosed twice daily beginning at Randomization to End of Study/Early Termination.

Locations

Country Name City State
Austria Medizinische Universitaet Innsbruck Innsbruck
Austria AKH Linz Linz
Belarus UZ Vitebsk Regional Childrens Clinical Centre Vitebsk
Belarus UZ Vitebsk Regional Childrens Clinical Centre Vitebsk
Bosnia and Herzegovina University Clinical Hospital Mostar Mostar Herzegovinaneretva Canton
Bosnia and Herzegovina Public Health Institution Hospital Dr Mladen Stojanovic Prijedor Republika Srpska
Bosnia and Herzegovina University Clinical Center Sarajevo Sarajevo Canton Sarajevo
Bosnia and Herzegovina University Clinical Center Tuzla Tuzla Canton Tuzla
Bulgaria Multiprofile Hospital for Active Treatment Puls AD Blagoevgrad
Bulgaria DCC Sv. Pantaleimon OOD Pleven
Bulgaria Military Medical Academy - Multiprofile Hospital for Active Treatment Pleven
Bulgaria MHAT Central Onco Hospital OOD Plovdiv
Bulgaria Medical Center Teodora Ruse
Bulgaria DCC Sveta Anna - Sofia Sofia
Bulgaria MHATNP Sveti Naum EAD Sofia
Bulgaria UMHAT Aleksandrovska Sofia
China The First Bethune Hospital of Jilin University Changchun Jilin
China The First Affiliated Hospital of Chongqing Medical University Chongqing Chongqing
China Shanghai Huashan Hospital, Neurology Department Shanghai Shanghai
Croatia University Hospital Center Split, Clinic for Neurology Split
Denmark Aarhus University Hospital Aarhus C
Denmark Odense University Hospital Odense C
France CHU d'Amiens - Picardie Amiens Cedex 1
France CHRU de Rennes - Hôpital Pontchaillou Rennes
France CHU d'Amiens Hopital Pontchaillou Rennes
Greece Athens Medical Center Athens
Greece Eginition Hospital Athens
Greece General Children's Hospital Penteli Athens
Greece University General Hospital of Thessaloniki "AHEPA" Thessaloniki
Hungary Semmelweis Egyetem, I. Sz. Gyermekgyogyaszati Klinika Budapest
Hungary Csongrad Megyei Egeszsegugyi Ellato Kozpont Hodmezovasarhely-Mako Hodmezovasarhely
Hungary Pest Megyei Flór Ferenc Kórhaz Kistarcsa
India St. John's Medical College Hospital Bangalore Karnataka
India Mangala Hospital & Mangala Kidney Foundation Mangalore Karnataka
India P D Hinduja National Hospital and Medical Research Centre Mumbai Maharashtra
India Getwell Hospital and Research Institute Nagpur Maharashtra
India Indraprastha Apollo Hospitals New Delhi Delhi
India KEM Hospital Research Centre Pune Maharashtra
India Sahyadri Speciality Hospital Pune Maharashtra
Korea, Republic of Keimyung University Dongsan Hospital Daegu Korea
Korea, Republic of Konkuk University medical center Seoul
Korea, Republic of Samsung Medical Center Seoul
Korea, Republic of Seoul National University Hospital Seoul
Lebanon Saint George Hospital - University Medical Center Beirut
Lebanon Ain Wazein Medical Village El Chouf
Malaysia Hospital Raja Permaisuri Bainun Ipoh Perak
Montenegro Pzu Neuron Bijelo Polje
Philippines Cebu Doctors' University Hospital Cebu City Cebu
Philippines Cebu Doctors' University Hospital, Rm Ph 7 Cebu City
Philippines Perpetual Succour Hospital Cebu City Cebu
Philippines Manila Doctors Hospital Manila
Philippines Metropolitan Medical Center Manila
Philippines University of Santo Tomas Hospital Manila
Philippines St. Luke's Medical Center Cathedral Heights Building Quezon City
Poland COPERNICUS Podmiot Leczniczy Spzoo Gdansk
Poland Neuro-Care Gabriela Klodowska Katowice
Poland NZOZ Novo Med Katowice
Poland NZOZ Wielospecjalistyczna Poradnia Lekarska SYNAPSIS Katowice
Poland NZOZ "HIPOKRATES II" Sp. z o.o. Krakow
Poland Instytut Medycyny Wsi im. Witolda Chodzki w Lublinie Lublin
Poland Solumed Centrum Medyczne Poznan
Poland NZOZ IGNIS dr n. med. Alicja Lobinska Swidnik
Poland Lecznica Medyczna ''Zycie" Warsaw
Romania Centrul Medical de Diagnostic si Tratament Ambulator Neomed Brasov
Romania CMI Neurologie, Neurofiziologie (EEG, EMG, PEC) Roceanu Adina Maria Bucuresti
Romania Sapiens Medical Center Bucuresti
Romania Spitalul Clinic de Urgenta "Prof. Dr. Nicolae Oblu" Iasi
Romania Spitalul Clinic de Urgente pentru Copii "Sf. Maria" Iasi
Romania Spitalul de Psihiatrie "Dr. Gh. Preda" Sibiu
Russian Federation TSBHI City Hospital No. 5 of Barnaul Barnaul
Russian Federation MAHI of the Order of the Red Banner of Labor City Clinical Hospital No. 1 Chelyabinsk
Russian Federation GBOU VPO "Kazan State Medical University" of Roszdrav Kazan Republic OF Tatarstan
Russian Federation Republican clinical hospital Kazan Republic OF Tatarstan
Russian Federation Non-state Healthcare Institution Moscow
Russian Federation Nizhmedklinika Nizhniy Novgorod Nizhegorodskaya Oblast
Russian Federation LLC City Neurological Center "Sibneiromed" Novosibirsk
Russian Federation Perm State Medical University n. a. acad. E.A. Vagner Perm
Russian Federation Perm State Medical University n. a. acad. E.A. Vagner Perm Permskiy KRAY
Russian Federation SPHI Leningrad Regional Psychoneurological Dispensary Pgt. Roshchino Leningrad Region
Russian Federation State Budgetary Healthcare Institution of Stavropol region Pyatigorsk Stavropol Region
Russian Federation FSBI V.M. Bekhterev National Research Medical Center for Saint Petersburg
Russian Federation SBHI of Saint Petersburg Psychoneurological Dispensary #5 Saint Petersburg
Russian Federation SBHI of Saint Petersburg Psychoneurological Dispensary #5 Saint Petersburg
Russian Federation SPHI Leningrad Regional Psychoneurological Dispensary Saint-Petersburg
Russian Federation GBOU VPO Smolensk State Medical University Smolensk
Russian Federation Regional State Budgetary Institution of Ministry of Health Smolensk
Russian Federation RSBHI Smolensk Regional Clinical Hospital Smolensk
Russian Federation SHI "Central Clinical Medical Unit Ulyanovsk
Russian Federation SHI "Central Clinical Medical Unit Ulyanovsk
Serbia Institute for Mental Health Belgrade
Serbia University Children's Hospital Belgrade
Serbia Clinical Center Kragujevac Kragujevac
Serbia Institute for Child and Youth Healthcare of Vojvodina Novi Sad Vojvodina
Slovakia Nemocnica s poliklinikou Hlohovec, s.r.o. Hlohovec
Slovakia Neurologicka ambulancia MUDr. Eva Gasparova Hlohovec
Spain Hospital Universitari de Bellvitge L'Hospitalet de Llobregat Barcelona
Turkey Eskisehir Osmangazi University Medical Faculty Department Of Neurology Eskisehir
Turkey Marmara University Pendik Training and Research Hospital Istanbul UST Kaynarca/pendik
Turkey Dokuz Eylul Ün. Tip Fakültesi Iç Hastaliklari Izmir
Turkey Celal Bayar University School of Medicine, Neurology Department Manisa
Ukraine Komunalnyi zaklad "Dnipropetrovska dytiacha miska klinichna likarnia No. 5" Dnipro
Ukraine Komunalnyi zaklad "Dnipropetrovska oblasna dytiacha klinichna likarnia" Dnipro
Ukraine Ivano-Frankivska oblasna dytiacha klinichna likarnia Ivano-Frankivsk
Ukraine Derzhavna ustanova "Instytut nevrolohii, psykhiatrii ta narkolohii Kharkiv
Ukraine Komunalne nekomertsiine pidpryiemstvo Kharkivskoi oblasnoi rady "Oblasna klinichna psykhiatrychna li Kharkiv
Ukraine Derzhavnyi zaklad "Ukrainskyi medychnyi tsentr reabilitatsii ditei z Kyiv
Ukraine Komunalnyi zaklad Lvivskoi oblasnoi rady "Lvivska oblasna klinichna likarnia" Lviv
Ukraine Komunalne nekomertsiine pidpryiemstvo "Odeskyi oblasnyi Odesa
Ukraine Komunalna ustanova "Odeska oblasna psykhiatrychna likarnia 2" S. Oleksandrivka Komintern. R-N, Odeska OBL.
Ukraine Oblasnyi klinichnyi tsentr neirokhirurhii ta nevrolohii, Uzhgorod
Ukraine Komunalna ustanova "Miska klinichna likarnia #2", nevrolohichne viddilennia Zaporizhzhia
United Kingdom The Barberry National Centre for Mental Health Birmingham WEST Midlands
United Kingdom Barts Health NHS Foundation Trust, The Royal London Hospital London
United Kingdom Salford Royal NHS Foundation Trust Salford
United Kingdom ABMU Local Health Board, Morriston Hospital Swansea
United States Ohio Clinical Research Partners, LLC Canton Ohio
United States Alexian Brothers Center for Psychiatric Research Hoffman Estates Illinois
United States Chinmay K. Patel, D.O. Hoffman Estates Illinois
United States St. Alexius Medical Center Hoffman Estates Illinois
United States Hawaii Pacific Neuroscience Honolulu Hawaii
United States Axcess Medical Research Loxahatchee Groves Florida
United States Pediatric Epilepsy Center of Central Florida Orlando Florida
United States Pediatric Neurology, PA Orlando Florida
United States Medsol Clinical Research Center Port Charlotte Florida
United States Rainier Clinical Research Center, Inc. Renton Washington
United States Road Runner Research, Ltd San Antonio Texas
United States Scott & White Memorial Hospital and Clinic Temple Texas

Sponsors (1)

Lead Sponsor Collaborator
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Countries where clinical trial is conducted

United States,  Austria,  Belarus,  Bosnia and Herzegovina,  Bulgaria,  China,  Croatia,  Denmark,  France,  Greece,  Hungary,  India,  Korea, Republic of,  Lebanon,  Malaysia,  Montenegro,  Philippines,  Poland,  Romania,  Russian Federation,  Serbia,  Slovakia,  Spain,  Turkey,  Ukraine,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Log-transformed (Log) 28-day Seizure Rate for All Primary Generalized Tonic-Clonic (PGTC) Seizures During 12-Week Double-Blind Treatment Phase All PGTC seizures experienced during treatment phase were recorded by the participants or their parents/legal guardian in a daily seizure diary. 28-day seizure rate for all PGTC seizures= ([number of seizures in the double blind treatment phase] divided by [number of days in double blind treatment phase minus {-} number of missing diary days in treatment phase])*28. For log-transformation, the quantity 1 was added to the 28-day seizure rate for all participants to account for any possible "0" seizure incidence. This resulted in final calculation as: log transformed (28-day seizure rate +1). Day 1 up to Week 12
Secondary Percentage of Participants With at Least 50 Percent (%) or Greater Reduction From Baseline in 28-day Primary Generalized Tonic-clonic (PGTC) Seizure Rate During the 12-Week Double-blind Treatment Phase Percentage of participants with 50% or greater reduction from baseline in 28-day seizure rate during the 12 week double blind treatment phase were reported. 28-day seizure rate for all PGTC seizures= ([number of seizures in the double blind treatment phase] divided by [number of days in double blind treatment phase minus {-} number of missing diary days in treatment phase])*28. Day 1 up to Week 12